|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
60,930,000 |
Market
Cap: |
1.55(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$10.11 - $25.45 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
10,000 |
1,687,666 |
Total Buy Value |
$0 |
$0 |
$138,828 |
$30,291,232 |
Total People Bought |
0 |
0 |
1 |
3 |
Total Buy Transactions |
0 |
0 |
1 |
3 |
Total Shares Sold |
0 |
75,715 |
115,161 |
179,650 |
Total Sell Value |
$0 |
$1,108,986 |
$1,602,723 |
$2,646,007 |
Total People Sold |
0 |
5 |
6 |
6 |
Total Sell Transactions |
0 |
14 |
25 |
43 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Morl Christopher John |
Chief Business Officer |
|
2020-01-07 |
4 |
AS |
$60.02 |
$99,035 |
D/D |
(1,650) |
0 |
|
-16% |
|
Morl Christopher John |
Chief Business Officer |
|
2020-01-07 |
4 |
OE |
$3.95 |
$6,518 |
D/D |
1,650 |
1,650 |
|
- |
|
Bristol James Arthur |
Director |
|
2020-01-03 |
4 |
AS |
$55.96 |
$458,195 |
D/D |
(7,989) |
0 |
|
-22% |
|
Bristol James Arthur |
Director |
|
2020-01-03 |
4 |
OE |
$1.89 |
$15,099 |
D/D |
7,989 |
7,989 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2020-01-03 |
4 |
AS |
$56.01 |
$1,800,923 |
D/D |
(31,422) |
0 |
|
-22% |
|
Taylor Michael Douglas |
Director |
|
2020-01-03 |
4 |
OE |
$1.89 |
$59,388 |
D/D |
31,422 |
31,422 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2020-01-03 |
4 |
AS |
$56.26 |
$249,993 |
D/D |
(4,359) |
0 |
|
-22% |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2020-01-03 |
4 |
OE |
$1.89 |
$8,239 |
D/D |
4,359 |
4,359 |
|
- |
|
Morl Christopher John |
Chief Business Officer |
|
2020-01-02 |
4 |
AS |
$57.74 |
$944,872 |
D/D |
(16,137) |
0 |
|
-11% |
|
Morl Christopher John |
Chief Business Officer |
|
2020-01-02 |
4 |
OE |
$3.95 |
$63,741 |
D/D |
16,137 |
16,137 |
|
- |
|
Bristol James Arthur |
Director |
|
2020-01-02 |
4 |
AS |
$57.51 |
$899,468 |
D/D |
(15,553) |
0 |
|
-11% |
|
Bristol James Arthur |
Director |
|
2020-01-02 |
4 |
OE |
$1.89 |
$29,395 |
D/D |
15,553 |
15,553 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2020-01-02 |
4 |
AS |
$57.50 |
$5,413,113 |
D/D |
(93,578) |
0 |
|
-11% |
|
Taylor Michael Douglas |
Director |
|
2020-01-02 |
4 |
OE |
$1.89 |
$176,862 |
D/D |
93,578 |
93,578 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2020-01-02 |
4 |
AS |
$57.54 |
$441,748 |
D/D |
(7,641) |
0 |
|
-11% |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2020-01-02 |
4 |
OE |
$1.89 |
$14,441 |
D/D |
7,641 |
7,641 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2019-12-23 |
4 |
S |
$68.21 |
$2,728,368 |
D/D |
(40,000) |
0 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2019-12-23 |
4 |
OE |
$1.89 |
$75,600 |
D/D |
40,000 |
40,000 |
|
- |
|
Flynn Daniel Lee |
Chief Scientific Officer |
|
2019-12-12 |
4 |
AS |
$60.00 |
$1,861,740 |
I/I |
(31,029) |
35,750 |
|
- |
|
Morl Christopher John |
Chief Business Officer |
|
2019-12-12 |
4 |
AS |
$60.00 |
$902,040 |
D/D |
(15,034) |
0 |
|
- |
|
Morl Christopher John |
Chief Business Officer |
|
2019-12-12 |
4 |
OE |
$3.95 |
$59,384 |
D/D |
15,034 |
15,034 |
|
- |
|
Flynn Daniel Lee |
Chief Scientific Officer |
|
2019-12-10 |
4 |
AS |
$55.00 |
$6,751,360 |
D/D |
(122,752) |
24,500 |
|
- |
|
Flynn Daniel Lee |
Chief Scientific Officer |
|
2019-12-10 |
4 |
OE |
$1.89 |
$232,001 |
D/D |
122,752 |
118,430 |
|
- |
|
Morl Christopher John |
Chief Business Officer |
|
2019-12-10 |
4 |
AS |
$55.00 |
$640,585 |
D/D |
(11,647) |
0 |
|
- |
|
Morl Christopher John |
Chief Business Officer |
|
2019-12-10 |
4 |
OE |
$3.95 |
$46,006 |
D/D |
11,647 |
11,647 |
|
- |
|
290 Records found
|
|
Page 8 of 12 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|